BNP Paribas Financial Markets’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14 | Hold |
6
| – | – | ﹤0.01% | 5869 |
|
|
2026
Q1 | $17 | Hold |
6
| – | – | ﹤0.01% | 5756 |
|
|
2025
Q4 | $19 | Hold |
6
| – | – | ﹤0.01% | 5674 |
|
|
2025
Q3 | $15 | Hold |
6
| – | – | ﹤0.01% | 5510 |
|
|
2025
Q2 | $29 | Hold |
6
| – | – | ﹤0.01% | 5379 |
|
|
2025
Q1 | $9 | Sell |
6
-337
| -98% | -$552 | ﹤0.01% | 5342 |
|
|
2024
Q4 | $652 | Hold |
343
| – | – | ﹤0.01% | 5139 |
|
|
2024
Q3 | $1.1K | Sell |
343
-3
| -0.9% | -$11 | ﹤0.01% | 3941 |
|
|
2024
Q2 | $2.42K | Hold |
346
| – | – | ﹤0.01% | 3804 |
|
|
2024
Q1 | $6.26K | Hold |
346
| – | – | ﹤0.01% | 3720 |
|
|
2023
Q4 | $3.67K | Sell |
346
-20
| -5% | -$241 | ﹤0.01% | 3775 |
|
|
2023
Q3 | $7.24K | Buy |
366
+11
| +3% | +$474 | ﹤0.01% | 3645 |
|
|
2023
Q2 | $27.1K | Buy |
355
+62
| +21% | +$5.02K | ﹤0.01% | 3564 |
|
|
2023
Q1 | $27.7K | Sell |
293
-5
| -2% | -$476 | ﹤0.01% | 3495 |
|
|
2022
Q4 | $29K | Sell |
298
-94
| -24% | -$13.6K | ﹤0.01% | 3500 |
|
|
2022
Q3 | $101K | Buy |
392
+158
| +68% | +$45.9K | ﹤0.01% | 3768 |
|
|
2022
Q2 | $43.6K | Buy |
234
+110
| +89% | +$10.5K | ﹤0.01% | 3591 |
|
|
2022
Q1 | $12.1K | Sell |
124
-160
| -56% | -$20.5K | ﹤0.01% | 3776 |
|
|
2021
Q4 | $46.4K | Buy |
284
+25
| +10% | +$5.49K | ﹤0.01% | 3756 |
|
|
2021
Q3 | $70.6K | Buy |
259
+198
| +325% | +$60.6K | ﹤0.01% | 3413 |
|
|
2021
Q2 | $24.2K | Sell |
61
-385
| -86% | -$180K | ﹤0.01% | 3483 |
|
|
2021
Q1 | $241K | Buy |
446
+261
| +141% | +$162K | ﹤0.01% | 2949 |
|
|
2020
Q4 | $69.9K | Sell |
185
-139
| -43% | -$55.3K | ﹤0.01% | 3396 |
|
|
2020
Q3 | $122K | Buy |
324
+197
| +155% | +$87K | ﹤0.01% | 3000 |
|
|
2020
Q2 | $62.4K | Sell |
127
-422
| -77% | -$188K | ﹤0.01% | 2951 |
|
|
2020
Q1 | $202K | Buy |
549
+412
| +301% | +$213K | ﹤0.01% | 2846 |
|
|
2019
Q4 | $96.8K | Sell |
137
-46
| -25% | -$31.7K | ﹤0.01% | 3308 |
|
|
2019
Q3 | $117K | Buy |
183
+70
| +62% | +$55.5K | ﹤0.01% | 3045 |
|
|
2019
Q2 | $99K | Sell |
113
-85
| -43% | -$58.5K | ﹤0.01% | 3041 |
|
|
2019
Q1 | $114K | Buy |
198
+187
| +1,700% | +$78.2K | ﹤0.01% | 3047 |
|
|
2018
Q4 | $3.01K | Sell |
11
-30
| -73% | -$11.9K | ﹤0.01% | 3724 |
|
|
2018
Q3 | $19.5K | Buy |
41
+2
| +5% | +$858 | ﹤0.01% | 3424 |
|
|
2018
Q2 | $17.5K | Sell |
39
-148
| -79% | -$93.8K | ﹤0.01% | 3550 |
|
|
2018
Q1 | $110K | Buy |
187
+5
| +3% | +$3.12K | ﹤0.01% | 3130 |
|
|
2017
Q4 | $113K | Buy |
182
+91
| +100% | +$65.4K | ﹤0.01% | 3234 |
|
|
2017
Q3 | $83.6K | Sell |
91
-6
| -6% | -$5.33K | ﹤0.01% | 2882 |
|
|
2017
Q2 | $90.3K | Buy |
97
+87
| +870% | +$85.3K | ﹤0.01% | 2866 |
|
|
2017
Q1 | $9.45K | Sell |
10
-41
| -80% | -$38.2K | ﹤0.01% | 3185 |
|
|
2016
Q4 | $40.9K | Sell |
51
-10
| -16% | -$9.01K | ﹤0.01% | 2917 |
|
|
2016
Q3 | $51.7K | Buy |
61
+29
| +91% | +$23.3K | ﹤0.01% | 2419 |
|
|
2016
Q2 | $26.4K | Buy |
+32
| New | +$34.8K | ﹤0.01% | 2491 |
|
|
2016
Q1 | – | Sell |
-179
| Closed | -$223K | – | 3043 |
|
|
2015
Q4 | $223K | Buy |
179
+20
| +13% | +$33.1K | ﹤0.01% | 1863 |
|
|
2015
Q3 | $214K | Buy |
159
+95
| +148% | +$157K | ﹤0.01% | 1907 |
|
|
2015
Q2 | $115K | Buy |
64
+50
| +357% | +$77.6K | ﹤0.01% | 2010 |
|
|
2015
Q1 | $23K | Buy |
+14
| New | +$20.7K | ﹤0.01% | 2308 |
|
|
2014
Q4 | – | Sell |
-31
| Closed | -$12.4K | – | 3057 |
|
|
2014
Q3 | $12.4K | Buy |
+31
| New | +$14.9K | ﹤0.01% | 3478 |
|
|
2014
Q2 | – | Sell |
-1
| Closed | -$302 | – | 3940 |
|
|
2014
Q1 | $302 | Sell |
1
-5
| -83% | -$3.35K | ﹤0.01% | 3142 |
|
|
2013
Q4 | $3.83K | Sell |
6
-83
| -93% | -$49.4K | ﹤0.01% | 3281 |
|
|
2013
Q3 | $52.8K | Sell |
89
-69
| -44% | -$31.1K | ﹤0.01% | 2501 |
|
|
2013
Q2 | $49.8K | Buy |
+158
| New | +$43.9K | ﹤0.01% | 2669 |
|
Other funds holding TCRT
VFT
VCM
TRCT
AAP
VGA
BTI
BNP Paribas Financial Markets's TCRT Position: Q2 2026 in Review
BNP Paribas Financial Markets held its Alaunos Therapeutics (TCRT) position steady in Q2 2026 at 6 shares worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #5869.
BNP Paribas Financial Markets first reported a position in TCRT in Q2 2013 and has held it in 50 quarters since. The position peaked at $241K in Q1 2021. 22 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.
- BNP Paribas Financial Markets held 6 shares of Alaunos Therapeutics worth $14 as of Q2 2026.
- BNP Paribas Financial Markets left its Alaunos Therapeutics share count unchanged in Q2 2026.
- Alaunos Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5869 holding.
- BNP Paribas Financial Markets first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 50 quarters since.
- BNP Paribas Financial Markets's Alaunos Therapeutics position peaked at $241K in Q1 2021.
- 22 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.